一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C 智谱 港股｜挂牌上市 据IPO早知道消息，北京智谱华章科技股份有限公司（以下简称"智谱"）于2026年1月8日正式以"2513"为股票代码在港交所主板 挂牌上市，成为"全球大模型第一股"。 智谱计划在本次IPO中发行37,419,500股H股。其中香港公开发售获1,159.46倍认购，国际发售获15.28倍认购。同时，智谱还在本 次IPO发行中引入了一个颇为多元化的基石投资阵容，涵盖北京核心国资、头部保险资金、大型公募基金、明星私募基金、产业 投资方等。以每股116.2港元的发行价计算，智谱本次IPO募资总额超43亿港元。 自2019年成立伊始，智谱就瞄向AGI，原创性提出基于自回归填空的通用预训练范式GLM（General Language Model）并研发出 中国首个预训练大模型框架。而后，智谱又陆续推出中国首个百亿模型、首个开源千亿模型、首个对话模型、首个多模态模型 和全球首个设备操控智能体，打造了世界范围内最为先进而全面的模型组合及智能体（AI Agent）产品，是国内罕有在原创技术 路线上与全球顶尖水平保持同步的厂商，故被誉 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 智谱 港股｜挂牌上市 据IPO早知道消息，北京智谱华章科技股份有限公司（以下简称"智谱"）于2026年1月8日正式 以"2513"为股票代码在港交所主板挂牌上市，成为"全球大模型第一股"。 智谱计划在本次IPO中发行37,419,500股H股。其中香港公开发售获1,159.46倍认购，国际发售获 15.28倍认购。同时，智谱还在本次IPO发行中引入了一个颇为多元化的基石投资阵容，涵盖北京核 心国资、头部保险资金、大型公募基金、明星私募基金、产业投资方等。以每股116.2港元的发行价 计算，智谱本次IPO募资总额超43亿港元。 自2019年成立伊始，智谱就瞄向AGI，原创性提出基于自回归填空的通用预训练范式GLM （General Language Model）并研发出中国首个预训练大模型框架。而后，智谱又陆续推出中国首 个百亿模型、首个开源千亿模型、首个对话模型、首个多模态模型和全球首个设备操控智能体，打造 了世界范围内最为先进而全面的模型组合及智能体（AI Agent）产品，是国内罕有在原创技术 ...

1月5日，中国证监会国际合作司发布《关于杭州德适生物科技股份有限公司境外发行上市及境内未上市 股份"全流通"备案通知书》。德适生物拟发行不超过3100.4万股境外上市普通股并在港交所上市。该公 司27名股东拟将所持合计8088万股境内未上市股份转为境外上市股份，并在港交所上市流通。 招股书披露，德适生物一直专注医学影像AI行业。公司专有的iMedImage™具有跨模态预训练架构，使 单一统一模型能支持19种医学影像模态(如染色体、CT、MRI、超声及病理)，并覆盖超过90%的临床医 学影像场景，包括生殖健康、血液系统恶性肿瘤及放射卫生。 根据弗若斯特沙利文资料，德适生物自主研发的iMedImage™是世界上参数规模最大的通用型医学影像 基座模型，已成功实现商业化，而且被认定为世界上首个商业化跨模态医学影像基座模型。 业绩方面，德适生物连续亏损。2023年、2024年及2025年前三季度，德适生物收入分别为5284.4万元、 7035.2万元、11161.6万元，年/期内亏损分别为5611.6万元、4337.5万元、3664.9万元。尽管公司营收增 长，但净利润连续亏损，两年多累计亏损1.36亿元。 从收入构成 ...

1月5日，中国证监会国际合作司发布《关于杭州德适生物科技股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书》。德适生物拟发行不超过 3100.4万股境外上市普通股并在香港联合交易所上市。该公司27名股东拟将所持合计8088万股境内未上市股份转为境外上市股份，并在香港联合交易所上市 流通。 根据弗若斯特沙利文资料，德适生物自主研发的iMedImageTM是世界上参数规模最大的通用型医学影像基座模型，已成功实现商业化，而且被认定为世界 上首个商业化跨模态医学影像基座模型。 附件："全流通"股东名称及转换数量 据招股书披露，德适生物一直专注医学影像AI行业。公司专有的iMedImageTM具有跨模态预训练架构，使单一统一模型能支持19种医学影像模态(如染色 体、CT、MRI、超声及病理)，并覆盖超过90%的临床医学影像场景，包括生殖健康、血液系统恶性肿瘤及放射卫生。 | 序号 | 股东名称 | 申请全流通股数(股) | | --- | --- | --- | | 1 | 宋宁 | 24,293,507 | | 2 | 杭州德适诺辉投资管理合伙企业(有限合伙) | 7,614,901 | | 3 | 杭州德 ...

智通财经APP获悉，1月5日，中国证监会国际合作司发布《关于杭州德适生物科技股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书》。德 适生物拟发行不超过3100.4万股境外上市普通股并在香港联合交易所上市。该公司27名股东拟将所持合计8088万股境内未上市股份转为境外上市股份，并在 香港联合交易所上市流通。 据招股书披露，德适生物一直专注医学影像AI行业。公司专有的iMedImageTM具有跨模态预训练架构，使单一统一模型能支持19种医学影像模态(如染色 体、CT、MRI、超声及病理)，并覆盖超过90%的临床医学影像场景，包括生殖健康、血液系统恶性肿瘤及放射卫生。 根据弗若斯特沙利文资料，德适生物自主研发的iMedImageTM是世界上参数规模最大的通用型医学影像基座模型，已成功实现商业化，而且被认定为世界 上首个商业化跨模态医学影像基座模型。 附件："全流通"股东名称及转换数量 | 序号 | 股东名称 | 申请全流通股数(股) | | --- | --- | --- | | 1 | 宋宁 | 24,293,507 | | 2 | 杭州德适诺辉投资管理合伙企业(有限合伙) | 7,614,901 | ...

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single-disease small models to the 2.0 era driven by a foundational large model, showcasing comprehensive diagnostic capabilities across multiple organs [1][2] Group 1 - Yimai Sunshine's stock rose over 6%, reaching HKD 17.23 with a trading volume of HKD 80.63 million following the announcement of the AIR product [1] - The AIR product is the first commercial outcome of the Yimai Medical's foundational large model ecosystem, designed to connect top hospitals with grassroots medical institutions through open interfaces [2] - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum from a single scan [1] Group 2 - The AIR product is expected to significantly shorten the AI product development cycle and reduce costs, facilitating standardized screening, intelligent diagnosis, and inclusive services in medical institutions [2] - The model promotes a positive feedback loop of "data-model-scenario" that enhances collaboration across the industry chain [2] - The technology behind the AIR product emphasizes efficient diagnosis, precise coverage, interactive collaboration, and seamless integration, fundamentally reconstructing the logic of medical imaging AI development and application [1]

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single disease small models to the 2.0 era driven by foundational large models, showcasing a milestone breakthrough in intelligent diagnosis [1][2] Group 1: Product Launch and Features - Yimai Sunshine's AIR product, developed by its incubated AI company Shanghai Yinghe Medical Technology, is the world's first AI-assisted diagnostic product based on a large medical imaging model [1] - The AIR product focuses on chest CT scans, enabling comprehensive detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - The product is built on the "Yinghe Mijia" model, which features multi-organ collaborative diagnosis capabilities, fundamentally restructuring the development and application logic of medical imaging AI [1] Group 2: Ecosystem and Market Impact - The AIR product serves as the first commercial outcome of the Yinghe Medical's foundational large model ecosystem, connecting top hospitals with grassroots medical institutions through open interfaces [2] - This model aims to create a positive cycle of "data feeding back model iteration, model driving scene implementation," significantly shortening AI product development cycles and reducing costs [2] - The initiative is expected to enhance screening standards, promote intelligent diagnosis, and facilitate inclusive services within the healthcare industry, effectively driving industry chain collaboration and establishing a "data-model-scene" closed-loop ecosystem [2]

Core Insights - The company Yimai Sunshine (02522) announced the launch of the world's first AI-assisted diagnostic product, AIR, developed by its affiliated AI company, Shanghai Yinghe Medical Technology Co., Ltd. This product marks a significant advancement in medical imaging AI, transitioning from the "single disease small model" era to the "foundation model-driven" era, showcasing capabilities for comprehensive diagnosis across multiple organs and diseases [1][2] Group 1 - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - AIR is based on the world's first cross-modal, full-process medical imaging foundation model, "Yinghe Mijia," which enhances diagnostic efficiency, precision, and seamless integration [1][2] - The launch of AIR signifies a shift from "single-point breakthroughs" to "systematic empowerment" in medical imaging AI, transforming the industry from "single disease detection" to "multi-disease collaborative analysis" [2] Group 2 - AIR serves as the first commercial outcome of the Yinghe Medical foundation model ecosystem, connecting top hospitals with grassroots medical institutions to create a positive feedback loop for data-driven model iteration and scene implementation [2] - This model is expected to significantly shorten AI product development cycles, reduce costs, and promote standardized screening, intelligent diagnosis, and inclusive services across the healthcare industry [2] - The technological innovation of "one scan, multiple disease simultaneous diagnosis" is anticipated to enhance the competitiveness and added value of the company's imaging center services [2]

Core Viewpoint - The launch of the AIR product by Shanghai Yinghe Medical Technology marks a significant advancement in medical imaging AI, transitioning from the "single disease small model" era to the "foundation large model driven" era, enabling comprehensive multi-organ diagnostic capabilities [1][2] Group 1: Product Development - The AIR product is the first commercial outcome of the Yinghe Medical's foundation large model ecosystem, designed to connect top hospitals with grassroots medical institutions through open interfaces [2] - The product focuses on chest CT scans, allowing for simultaneous detection and diagnosis of multiple organs, including the lungs, pleura, and mediastinum, covering all common diseases in that area [1][2] Group 2: Technological Innovation - AIR represents a technological innovation that enhances diagnostic efficiency and accuracy, fundamentally restructuring the development and application logic of medical imaging AI [1] - The product's ability to perform "one scan, multiple disease simultaneous diagnosis" significantly boosts the competitiveness and added value of the group's imaging center services [2] Group 3: Industry Impact - The introduction of AIR signifies a shift in the medical imaging AI industry from "single-point breakthroughs" to "systematic empowerment," evolving from a "tool assistance" model to a "diagnostic partner" model [2] - This new paradigm supports health screening, precision diagnosis, and telemedicine, promoting a transition from "single disease detection" to "comprehensive disease collaborative analysis" [2]

Core Insights - The company Yimai Sunshine (02522.HK) announced the launch of the world's first AI-assisted diagnostic product for chest CT scans, named AIR, developed by its incubated AI company Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. This marks a significant advancement in medical imaging AI from the "single disease small model" era to the "foundation large model-driven" era [1][2] Group 1 - The AIR product is designed to perform comprehensive diagnostics across multiple organs, focusing initially on chest CT scans, enabling simultaneous detection and diagnosis of conditions in the lungs, pleura, and mediastinum [1] - The product is based on the world's first cross-modal, full-process medical imaging foundation large model, "Yinghe Mijia," showcasing its capabilities in multi-organ collaborative diagnosis and efficient integration [1][2] - The launch of the AIR product signifies a shift in medical imaging AI from "point breakthroughs" to "systematic empowerment," transforming the role of AI from a diagnostic tool to a diagnostic partner [2] Group 2 - The AIR product facilitates a positive feedback loop by connecting top hospitals with grassroots medical institutions through open interfaces, which will shorten AI product development cycles and reduce costs [2] - This model aims to standardize screening, enhance diagnostic intelligence, and promote inclusive services, thereby driving collaboration across the industry and establishing a closed-loop ecosystem of "data-model-scenario" [2] - The technological innovation of "one scan, multiple disease simultaneous diagnosis" is expected to significantly enhance the competitiveness and added value of the company's imaging center services [2]